GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
GRAIL, Inc.'s Chief Growth Officer Andrew John Partridge reported an automatic sale of common stock tied to equity compensation. On the transaction date, an executing broker sold 1,491 shares in open-market trades at a weighted average price of $61.08 per share to cover withholding taxes when an award vested and shares were delivered. After these sell-to-cover transactions, Partridge directly held 163,738 shares of GRAIL common stock, indicating this was a small, tax-related disposition relative to his remaining stake.
Ofman Joshua J. reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. director and Chief Executive Officer Joshua J. Ofman received equity compensation in the form of common‑stock–settled restricted stock units. He was granted 27,901 shares and 3,154 shares of common stock-equivalent awards, not purchased on the open market. These RSUs vest in four substantially equal annual installments beginning on May 31, 2027, contingent on continued service, and will be settled in common stock upon vesting. Following these awards, he directly holds 402,271 shares of GRAIL common stock.
Gr-al Holdings, Inc. files a Form 144 reporting a proposed sale of 2,914 shares. The filing states these shares were acquired upon vesting of restricted stock units awarded under the issuer's equity incentive plans on 06/03/2026.
The notice also lists prior reported dispositions by Andrew Partridge of 1,445 shares on 03/09/2026 (value $69,201.05) and 35,240 shares on 04/08/2026 (value $1,759,180.80). Shares outstanding are shown as 43,073,334 as of 06/03/2026.
GRAIL, Inc. disclosed the initial holdings of Chief Growth Officer Andrew John Partridge on a Form 3. He directly owns 165,229 shares of GRAIL common stock. This filing records his starting equity position as an officer, without reporting any recent stock purchases or sales.
GRAIL, Inc. updated the employment terms for its new Chief Executive Officer, Dr. Joshua Ofman, and showcased detailed clinical data for its Galleri multi‑cancer early detection test. The amended offer letter makes Dr. Ofman the principal executive officer as of June 1, 2026, with an annual base salary of $800,000 and a variable compensation plan target equal to 100% of salary from that date. He will receive restricted stock units valued at $2,000,000, vesting over four years, and significant severance protections, including up to 24 months of salary, 200% of target bonus, full equity acceleration, and extended healthcare benefits if he is terminated without cause or resigns for good reason in connection with a change in control.
The accompanying investor presentation from ASCO 2026 highlights results from the NHS‑Galleri and PATHFINDER 2 trials, covering roughly 180,000 participants. Adding Galleri to standard screening reduced Stage IV cancers for 12 deadly cancer types by more than 20% in incident screening rounds, increased early‑stage (Stage I/II) detections by about 16%, and quadrupled screening‑detected cancers versus standard screening alone. The test showed positive predictive value around 52–60%, a false positive rate below 0.5%, and high accuracy in predicting cancer signal origin, with no serious study‑related adverse events reported.
Baker Bros. Advisors, together with affiliated reporting persons, reports beneficial ownership of 4,028,614 shares of GRAIL, Inc. common stock, equal to 9.8% of 41,134,219 shares outstanding as of March 31, 2026. The reported position reflects holdings through two funds: 667, L.P. (278,073 shares, 0.7%) and Baker Brothers Life Sciences, L.P. (3,750,541 shares, 9.1%). The filing states pre-funded warrants exercisable at $0.001 per share are subject to a 4.99% ownership cap (the "Maximum Percentage") that can be increased up to 19.99% by written notice becoming effective on the 61st day after delivery; because of the cap the funds cannot presently exercise those warrants.
Farallon group amends its Schedule 13G/A to report beneficial ownership in GRAIL, Inc. The filing states the Farallon Funds hold an aggregate of 2,682,663 Shares and 571,021 Pre‑Funded Common Stock Purchase Warrants, each exercisable for one Share, and the Warrants are assumed exercisable within 60 days. The Warrants include a Beneficial Ownership Limitation that prevents exercise above 9.99% of outstanding Shares; the filing says that limitation does not currently restrict exercises. The report lists the Farallon Funds, related general partners, and 15 individual reporting persons and disclaims beneficial ownership by certain partners and individuals in specific circumstances.
GRAIL, Inc. reported strong first-quarter 2026 growth, with total revenue of $40.8 million, an increase of 28% year over year. Galleri test revenue reached $39.8 million, up 37%, as test volume grew 50% to more than 56,000 tests.
The company recorded a net loss of $93.2 million, an improvement of 12%, and a gross loss of $14.3 million. Non-GAAP adjusted gross profit was $19.7 million, while adjusted EBITDA was a loss of $79.9 million, a 19% improvement.
GRAIL ended the quarter with $823.1 million in cash, cash equivalents, and short-term marketable securities. The FDA accepted its Premarket Approval application for the Galleri test, and GRAIL plans to integrate Galleri into Epic’s electronic health record platform to broaden access.
GRAIL, Inc. has issued its 2026 proxy statement for a virtual annual meeting on June 18, 2026, asking shareholders to elect two Class II directors and ratify Ernst & Young LLP as auditor for 2026. Shareholders of record on April 22, 2026, when 42,916,593 common shares were outstanding, may vote.
The filing highlights a planned leadership transition, with President Joshua Ofman becoming Chief Executive Officer on June 1, 2026, succeeding Robert Ragusa after a long-term succession process. It describes GRAIL’s focus on its Galleri multi-cancer early detection test, including completion of a premarket approval submission to the FDA and large clinical studies such as the 140,000-person NHS Galleri Trial and 35,000-person PATHFINDER 2.
The proxy details a classified six‑member board, director independence, and committee structures. It also discloses 2025 executive pay, including total compensation of $8.1 million for the CEO, $3.1 million for the CFO (including a $250,000 discretionary bonus tied to financing), and $4.3 million for the President, along with RSU grants under the 2024 Incentive Award Plan.